UYG $40.95 -1.1586%
PCIP.L $54.84 -2.0714%
0RQF.L $0.54 0.5607%
MDLY $5.88 0%
DCOMP $13.90 0.361%
ASNS $3.56 0%
I500.L $5.31 0.3353%
DSAQ $10.57 0.1896%
EXAI $5.08 -4.1509%
CANE $13.84 0.3626%
IBDS $23.83 -0.1676%
USEG $1.31 0.7692%
ERA.PA $86.80 1.4019%
2015.HK $114.10 -1.5531%
RCLF $10.32 -0.1934%
5VJ.SI $0.41 0%
CY6U.SI $1.06 -0.9346%
0655.HK $0.49 4.2553%
WTT $1.77 -0.0057%
OXT.L $27.50 0%
DNMR $2.99 -2.7687%
QNST $7.24 1.4727%
BC94.L $1 195.66 -0.4443%
UAL $44.45 -1.4086%
0LS8.L $71.59 -0.4035%
LGH $35.29 -0.5913%
YUM $137.71 0.2694%
SP $34.70 0.3761%
O $61.64 -0.267%
1222.HK $0.05 2.0833%
ARTE $10.43 0%
BLUT3.SA $5.14 0%
ALBOA.PA $31.20 -0.3195%
8535.HK $0.14 0.7463%
EB $6.97 -3.931%
BCACU $23.20 0%
6865.HK $21.65 -2.0362%
1426.HK $2.39 0.8439%
MCAG $10.52 2.7344%
FWDB $25.78 0%
JBL $78.94 -0.1012%
MTA $4.90 -0.2037%
DXCM $121.35 0.2313%
GLEEU $10.16 0%
RXRA $10.04 0%
VLDR $1.26 0%
SPNE $9.54 0%
FFBC $18.08 -0.6868%
MYOV $26.98 0%
DFNS $12.85 0%
0J72.L $9.24 -2.0409%
SIJ $15.49 0.2096%
0KYZ.L $233.05 -0.8509%
6830.HK $2.38 -0.4184%
ASA $16.70 -0.0598%
UBIF.L $1 275.75 1.25%
ALQGC.PA $0.17 -3.624%
SUI $133.47 -1.8242%
PCSB $19.04 0%
GCO $30.10 -2.241%
BCOR $27.19 0%
0KJD.L $67.76 -1.0261%
0021.HK $0.12 0%
BDX $251.41 0.002%
0J5I.L $140.96 0.113%
RZV $84.75 -1.3789%
GTPAU $9.97 0%
BALM4.SA $10.14 -0.5882%
NTSX $35.14 -0.8745%
DGL $51.96 0%
YSG $0.85 1.3562%
2223.HK $0.40 0%
BLIN $0.95 0%
S61.SI $2.64 -0.3774%
3LFB.L $0.33 -4.4955%
TSE $12.93 -6.032%
KSM $8.33 0.1142%
CIZ $31.57 -0.2225%
FTAD.L $5.10 0.2062%
JCGI.L $272.50 -1.8018%
0RS2.L $49.50 -0.4112%
HMA-UN $10.48 0%
PPH.NZ $1.41 0%
ARTEU $10.45 0.0958%
AAXJ $65.08 -1.6324%
0498.HK $0.48 -12.037%
HTCF.L $389.00 0%
ENOG.L $1 211.00 -0.0825%
8317.HK $0.37 0%
0JTT.L $32.09 0.4724%
COF-PN $15.14 0.7656%
ITAQ $10.52 1.2512%
FITE $45.29 0.5207%
TPOR $22.85 -0.6526%
PGF $13.95 0.2811%
IUMF.L $790.88 0.8287%
TCRX $3.85 -14.44%
SMHI $7.75 -1.8987%
CORR-PA $5.70 -1.2149%
3380.HK $0.89 -1.1111%
Eng
Логотип
Eng
Лого

Zynerba Pharmaceuticals, Inc. 0M40.L

$0.37

+$0.02 (5.44%)
На 18:02, 12 мая 2023

Ключевые показатели

  • Marketcap

    133881.00000000

  • week52high

    1.55

  • week52low

    0.36

  • Revenue

  • P/E TTM

    0

  • Beta

    1.73079500

  • EPS

    -0.96200000

  • Last Dividend

    0.00000000

  • Next Earnings Date

    15 мая 2023 г. в 11:00

Описание компании

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек